FY2017 Earnings Estimate for NuVasive, Inc. (NUVA) Issued By Gabelli

NuVasive, Inc. (NASDAQ:NUVA) – Gabelli upped their FY2017 EPS estimates for NuVasive in a note issued to investors on Monday. Gabelli analyst J. Tsai now anticipates that the brokerage will post earnings of $2.00 per share for the year, up from their previous estimate of $1.95. Gabelli also issued estimates for NuVasive’s FY2018 earnings at $2.40 EPS and FY2019 earnings at $2.80 EPS.

NuVasive (NASDAQ:NUVA) last issued its earnings results on Thursday, February 9th. The medical device company reported $0.53 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.51 by $0.02. NuVasive had a return on equity of 12.26% and a net margin of 3.29%. The firm had revenue of $271.10 million for the quarter, compared to analysts’ expectations of $261.25 million. During the same quarter last year, the business earned $0.35 earnings per share. The company’s revenue was up 25.9% compared to the same quarter last year.

This news story was originally reported by Web Breaking News and is the property of of Web Breaking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The correct version of this news story can be read at http://www.webbreakingnews.com/2017/02/17/fy2017-earnings-estimate-for-nuvasive-inc-nuva-issued-by-gabelli.html.

Earnings History and Estimates for NuVasive (NASDAQ:NUVA)

NUVA has been the subject of a number of other reports. Zacks Investment Research downgraded NuVasive from a “buy” rating to a “hold” rating in a research report on Tuesday, October 25th. Canaccord Genuity set a $69.00 price objective on NuVasive and gave the stock a “buy” rating in a research report on Monday, January 23rd. TheStreet downgraded NuVasive from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 25th. Jefferies Group LLC restated a “buy” rating and set a $72.00 price objective on shares of NuVasive in a research report on Wednesday, October 26th. Finally, Barclays PLC restated an “overweight” rating and set a $80.00 price objective (up from $76.00) on shares of NuVasive in a research report on Thursday. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. NuVasive has a consensus rating of “Buy” and a consensus target price of $70.36.

Shares of NuVasive (NASDAQ:NUVA) traded down 0.03% during trading on Wednesday, reaching $73.95. The company’s stock had a trading volume of 174,338 shares. The company’s 50 day moving average price is $70.32 and its 200 day moving average price is $65.97. NuVasive has a 12 month low of $37.95 and a 12 month high of $75.10. The firm has a market cap of $3.74 billion, a PE ratio of 107.17 and a beta of 0.86.

In other NuVasive news, Director Lesley H. Howe sold 6,049 shares of the company’s stock in a transaction dated Tuesday, February 14th. The stock was sold at an average price of $73.26, for a total value of $443,149.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Matthew Link sold 10,303 shares of the company’s stock in a transaction dated Monday, December 12th. The stock was sold at an average price of $67.99, for a total value of $700,500.97. The disclosure for this sale can be found here. 4.70% of the stock is owned by corporate insiders.

This news story was originally reported by Web Breaking News and is the property of of Web Breaking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The correct version of this news story can be read at http://www.webbreakingnews.com/2017/02/17/fy2017-earnings-estimate-for-nuvasive-inc-nuva-issued-by-gabelli.html.

Institutional investors have recently modified their holdings of the company. Fortaleza Asset Management Inc. boosted its position in shares of NuVasive by 59.2% in the fourth quarter. Fortaleza Asset Management Inc. now owns 3,065 shares of the medical device company’s stock worth $206,000 after buying an additional 1,140 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in shares of NuVasive during the fourth quarter worth about $1,130,000. Empire Life Investments Inc. purchased a new position in shares of NuVasive during the fourth quarter worth about $1,214,000. Guggenheim Capital LLC boosted its position in shares of NuVasive by 15.5% in the fourth quarter. Guggenheim Capital LLC now owns 182,958 shares of the medical device company’s stock worth $12,324,000 after buying an additional 24,534 shares during the last quarter. Finally, Seven Eight Capital LP purchased a new position in shares of NuVasive during the fourth quarter worth about $1,287,000.

NuVasive Company Profile

Nuvasive, Inc is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion.

5 Day Chart for NASDAQ:NUVA

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.